PL3386500T3 - Selektywne antagonisty receptora estrogenowego na bazie benzotiofenu - Google Patents

Selektywne antagonisty receptora estrogenowego na bazie benzotiofenu

Info

Publication number
PL3386500T3
PL3386500T3 PL16874012.4T PL16874012T PL3386500T3 PL 3386500 T3 PL3386500 T3 PL 3386500T3 PL 16874012 T PL16874012 T PL 16874012T PL 3386500 T3 PL3386500 T3 PL 3386500T3
Authority
PL
Poland
Prior art keywords
benzothiophene
estrogen receptor
selective estrogen
based selective
receptor downregulators
Prior art date
Application number
PL16874012.4T
Other languages
English (en)
Inventor
Gregory R. Thatcher
Rui XIONG
Jiong ZHAO
Debra A. Tonetti
Original Assignee
The Board Of Trustees Of The University Of Illinois
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Board Of Trustees Of The University Of Illinois filed Critical The Board Of Trustees Of The University Of Illinois
Publication of PL3386500T3 publication Critical patent/PL3386500T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/64—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
PL16874012.4T 2015-12-09 2016-12-09 Selektywne antagonisty receptora estrogenowego na bazie benzotiofenu PL3386500T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562264971P 2015-12-09 2015-12-09
US201662322878P 2016-04-15 2016-04-15
PCT/US2016/066023 WO2017100712A1 (en) 2015-12-09 2016-12-09 Benzothiophene-based selective estrogen receptor downregulators

Publications (1)

Publication Number Publication Date
PL3386500T3 true PL3386500T3 (pl) 2023-03-13

Family

ID=59013340

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16874012.4T PL3386500T3 (pl) 2015-12-09 2016-12-09 Selektywne antagonisty receptora estrogenowego na bazie benzotiofenu

Country Status (24)

Country Link
US (7) US20170166551A1 (pl)
EP (2) EP3386500B1 (pl)
JP (2) JP6920709B2 (pl)
KR (1) KR20180088457A (pl)
CN (2) CN108699024B (pl)
AU (1) AU2016366680B2 (pl)
BR (1) BR112018011607B1 (pl)
CA (1) CA3008020C (pl)
DK (1) DK3386500T3 (pl)
EA (1) EA038180B1 (pl)
ES (1) ES2935125T3 (pl)
HR (1) HRP20221462T1 (pl)
HU (1) HUE061065T2 (pl)
IL (1) IL259566B (pl)
LT (1) LT3386500T (pl)
MX (2) MX2018007079A (pl)
NZ (1) NZ743651A (pl)
PL (1) PL3386500T3 (pl)
PT (1) PT3386500T (pl)
RS (1) RS63791B1 (pl)
RU (1) RU2747802C2 (pl)
SI (1) SI3386500T1 (pl)
WO (2) WO2017100715A1 (pl)
ZA (2) ZA201803422B (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2018007079A (es) * 2015-12-09 2018-11-12 The Board Of Trustees Of Univ Of Illinois Reguladores a la baja del receptor de estrogeno selectivo de benzotiofeno.
US10599150B2 (en) 2016-09-29 2020-03-24 The Charles Stark Kraper Laboratory, Inc. Autonomous vehicle: object-level fusion
AU2018205262A1 (en) * 2017-01-06 2019-07-11 G1 Therapeutics, Inc. Combination therapy for the treatment of cancer
CA3052810A1 (en) 2017-02-10 2018-08-16 G1 Therapeutics, Inc. Benzothiophene estrogen receptor modulators
AU2018291026B2 (en) 2017-06-29 2022-09-01 G1 Therapeutics, Inc. Morphic forms of GIT38 and methods of manufacture thereof
US11759450B2 (en) 2018-02-06 2023-09-19 The Board Of Trustees Of The University Of Illinois Substituted benzothiophene analogs as selective estrogen receptor degraders
US10741313B1 (en) 2019-02-06 2020-08-11 Eaton Intelligent Power Limited Bus bar assembly with integrated surge arrestor
US11249184B2 (en) 2019-05-07 2022-02-15 The Charles Stark Draper Laboratory, Inc. Autonomous collision avoidance through physical layer tracking
WO2021007330A1 (en) * 2019-07-08 2021-01-14 Dermavant Sciences GmbH Cerdulatinib-containing topical skin pharmaceutical compositions and uses thereof
CN115710248A (zh) * 2022-11-18 2023-02-24 南京中医药大学 新型选择性***受体下调剂化合物、制备方法及用途

Family Cites Families (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4418068A (en) 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
GB8327256D0 (en) 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
DE4126999A1 (de) 1991-08-16 1993-02-18 Basf Ag Herbizide mittel, enthaltend 3-aminobenzo(b)thiophene als antidots
EP0545478A1 (en) 1991-12-03 1993-06-09 MERCK SHARP & DOHME LTD. Heterocyclic compounds as tachykinin antagonists
JPH05345780A (ja) * 1991-12-24 1993-12-27 Kumiai Chem Ind Co Ltd ピリミジンまたはトリアジン誘導体及び除草剤
SK280617B6 (sk) 1992-01-16 2000-05-16 Hoechst Aktiengesellschaft Arylcykloalkylové deriváty, spôsob ich prípravy, f
TW366342B (en) 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
EP0622673B1 (en) 1993-04-24 1998-02-04 Kodak Limited Photographic colour couplers and photographic materials containing them
US5478847A (en) 1994-03-02 1995-12-26 Eli Lilly And Company Methods of use for inhibiting bone loss and lowering serum cholesterol
US5834468A (en) 1995-07-07 1998-11-10 Zeneca Limited Substituted aryl and heteroaryl compounds as E-type prostaglandin antagonists
US6458811B1 (en) 1996-03-26 2002-10-01 Eli Lilly And Company Benzothiophenes formulations containing same and methods
US5780497A (en) 1996-04-19 1998-07-14 American Home Products Corporation 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents
TW397821B (en) 1996-04-19 2000-07-11 American Home Produits Corp 3-[4-(2-phenyl-indole-1-ylmethyl)-phenyl]-acrylamides and 2-phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol as well as pharmaceutical compositions of estrogenic agents thereof
US5880137A (en) 1996-04-19 1999-03-09 American Home Products Corporation 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents
US5998402A (en) 1996-04-19 1999-12-07 American Home Products Corporation 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents
RU2214236C2 (ru) * 1997-08-15 2003-10-20 Дьюк Юниверсити Способ профилактики или лечения эстрогензависимых заболеваний и расстройств
AU9399898A (en) 1997-10-03 1999-04-27 Eli Lilly And Company Benzothiophenes
US6005102A (en) 1997-10-15 1999-12-21 American Home Products Corporation Aryloxy-alkyl-dialkylamines
UA68365C2 (en) 1997-11-06 2004-08-16 Wyeth Corp Peroral contraception by combination of anti-estrogen and progestin
US6326392B1 (en) 1997-11-06 2001-12-04 American Home Products Corporation Anti-estrogen plus progestin containing oral contraceptives
US6479535B1 (en) 1998-05-15 2002-11-12 Wyeth 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations
US6583170B1 (en) 1998-05-15 2003-06-24 Wyeth 2-Phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol and estrogen formulations
GB0000313D0 (en) 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
CO5271697A1 (es) 2000-01-12 2003-04-30 Pfizer Prod Inc Composiciones y procedimientos para el tratamiento de afecciones que responden a un aumento de testosterona
CO5271696A1 (es) 2000-01-12 2003-04-30 Pfizer Prod Inc Procedimiento para reducir la morbilidad y el riesgo de mortalidad
CO5271709A1 (es) 2000-01-12 2003-04-30 Pfizer Prod Inc Composiciones y procedimientos para el y tratamiento de afecciones que responden a estrogenos
CO5251465A1 (es) 2000-01-26 2003-02-28 Pfizer Prod Inc Composiciones y procedimientos para tratar la osteoporosis y reducir el colesterol
US7091240B2 (en) 2000-03-10 2006-08-15 Oxigene, Inc. Tubulin binding ligands and corresponding prodrug constructs
US20020013327A1 (en) 2000-04-18 2002-01-31 Lee Andrew G. Compositions and methods for treating female sexual dysfunction
WO2002003992A2 (en) 2000-07-06 2002-01-17 Wyeth Use of substituted indole compounds for treating prosthesis-related bone degeneration
AR030064A1 (es) 2000-07-06 2003-08-13 Wyeth Corp Metodos para inhibir los efectos uterotroficos de los agentes estrogenicos
AU2001273144A1 (en) 2000-07-06 2002-01-21 Wyeth Use of substituted indole compounds for treating neuropeptide y-related conditions
CN1635885A (zh) 2000-07-06 2005-07-06 惠氏公司 应用取代吲哚化合物增强一氧化氮合酶活性
WO2002003986A2 (en) 2000-07-06 2002-01-17 Wyeth Use of substituted indole compounds for treating breast disorders
JP2004502729A (ja) 2000-07-06 2004-01-29 ワイス Ｓｓｒｉおよびエストロゲン剤の組み合わせ
CA2414060A1 (en) 2000-07-06 2002-01-17 Wyeth Combinations of statins, estrogenic agents and optionally estrogens
MXPA02012897A (es) 2000-07-06 2003-10-24 Wyeth Corp Combinaciones de bisfosfonatos, agentes estrigenicos y opcionalmente estrogenos.
AU2001271781A1 (en) 2000-07-06 2002-01-21 Wyeth Use of substituted indole compounds for treating sphincter incontinence
AU2001271782A1 (en) 2000-07-06 2002-01-21 Wyeth Use of substituted insole compounds for treating excessive intraocular pressure
EP1177787A3 (en) 2000-07-28 2003-09-10 Pfizer Products Inc. Use of an estrogen agonist/antagonist for treating cataracts
CA2416976C (en) 2000-08-11 2008-05-20 Wyeth Treatment of estrogen receptor positive carcinoma with a rapamycin and an antiestrogen
EP1192945A3 (en) 2000-09-21 2004-03-03 Pfizer Products Inc. Use of an estrogen agonist/antagonist for treating osteoarthritis
IL145838A (en) 2000-10-16 2008-11-03 Pfizer Prod Inc Use of an estrogen agonist / antagonist to produce a drug for the treatment of vaginitis
AU781168B2 (en) 2001-01-26 2005-05-12 Pfizer Products Inc. Method of treating certain cancers using an estrogen agonist/antagonist
EP1527076B1 (en) * 2002-07-24 2005-12-28 Eli Lilly And Company Dihydro-dibenzo[b,e]oxepine based selective estrogen receptor modulators, compositions and methods
WO2005016929A1 (en) 2003-08-15 2005-02-24 Astrazeneca Ab Fused heterocylcles as inhibitors of glutamate racemase (muri)
JP2005129430A (ja) 2003-10-27 2005-05-19 Konica Minolta Holdings Inc 光電変換材料用半導体、光電変換素子及び太陽電池
FR2862646B1 (fr) * 2003-11-20 2006-02-24 Merck Sante Sas Nouveaux composes antidiabetiques contenant des derives benzofuranes, benzothiophenes
BRPI0417407A (pt) 2003-12-15 2007-04-03 Theramex derivados de 1-n-fenil-amino-1h-imidazol e composições farmacêuticas contendo estes
US7399767B2 (en) 2005-01-21 2008-07-15 Ortho-Mcneil Pharmaceutical, Inc. Heterocyclic benzo[c]chromene derivatives useful as modulators of the estrogen receptors
US8278290B2 (en) 2005-02-14 2012-10-02 Biononics Limited Tubulin polymerisation inhibitors
AU2007211840B2 (en) 2006-02-03 2012-03-01 Bionomics Limited Substituted benzofurans, benzothiophenes, benzoselenophenes and indoles and their use as tubulin polymerisation inhibitors
US8933130B2 (en) 2006-06-23 2015-01-13 Radius Health, Inc. Treatment of vasomotor symptoms with selective estrogen receptor modulators
EP1947085A1 (en) 2007-01-19 2008-07-23 Laboratorios del Dr. Esteve S.A. Substituted indole sulfonamide compounds, their preparation and use as medicaments
CN101796043A (zh) 2007-07-25 2010-08-04 霍夫曼-拉罗奇有限公司 苯并呋喃-和苯并[b]噻吩-2-羧酸酰胺衍生物及其作为阻胺3受体调节剂的应用
WO2010093578A1 (en) 2009-02-10 2010-08-19 Glaxo Group Limited Indolinyl-, benzofuranyl-, and benzothienyl- amides as modulators of chemokine receptors
EP2427430B1 (en) 2009-05-04 2014-09-10 The Royal Institution for the Advancement of Learning/McGill University 5-oxo-ete receptor antagonist compounds
IN2012DN02534A (pl) 2009-09-16 2015-08-28 Avila Therapeutics Inc
WO2011136828A1 (en) 2010-04-27 2011-11-03 The Johns Hopkins University Immunogenic compositions and methods for treating neoplasia
WO2011156518A2 (en) 2010-06-10 2011-12-15 Aragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
US8853423B2 (en) 2010-06-17 2014-10-07 Seragon Pharmaceuticals, Inc. Indane estrogen receptor modulators and uses thereof
US8642632B2 (en) 2010-07-02 2014-02-04 Radius Health, Inc. Selective androgen receptor modulators
GB2483736B (en) 2010-09-16 2012-08-29 Aragon Pharmaceuticals Inc Estrogen receptor modulators and uses thereof
US10005750B2 (en) 2010-10-06 2018-06-26 J-Pharma Co., Ltd. Developing potent urate transporter inhibitors: compounds designed for their uricosuric action
EP2655367B1 (en) 2010-12-24 2016-07-06 Merck Sharp & Dohme B.V. N-substituted azetidine derivatives
DE102011087987A1 (de) 2011-12-08 2013-06-13 Bayer Intellectual Property Gmbh 6,7-Dihydro-5H-benzo[7]annulen-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
CN104114551B (zh) 2011-12-14 2017-01-18 塞拉根制药公司 氟化***受体调节剂及其用途
PE20150099A1 (es) 2011-12-16 2015-01-30 Olema Pharmaceuticals Inc Compuestos novedosos de benzopirano, composiciones y usos de los mismos
JP2015505562A (ja) * 2012-01-31 2015-02-23 ノバルティス アーゲー Ｒｔｋ阻害剤と抗エストロゲン剤との組合せ、およびがん治療のためのその使用
JP6154887B2 (ja) 2012-03-20 2017-06-28 セラゴン ファーマシューティカルズ，インク． エストロゲン受容体モジュレーターおよびその使用
EP2871891B1 (en) 2012-08-01 2017-03-29 Huawei Technologies Co., Ltd. Synchronization method, apparatus, and system
US20150203285A1 (en) 2012-09-05 2015-07-23 Kjoninklijke Philips N.V. Capsule for the preparation of beverages, device and method
US20150284357A1 (en) 2012-10-24 2015-10-08 Gregory R. Thatcher Compositions and methods for treating estrogen-related medical disorders
US9475791B2 (en) * 2012-10-24 2016-10-25 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating estrogen-related medical disorders
MA38325B1 (fr) * 2013-02-19 2019-03-29 Novartis Ag Dérivés de benzothiophène et compositions correspondantes en tant qu'agents de dégradation sélectifs des récepteurs des œstrogènes
CN105121413B (zh) 2013-03-14 2018-09-14 赛拉根医药股份有限公司 多环***受体调节剂及其用途
LT3004090T (lt) 2013-05-28 2018-01-10 Astrazeneca Ab Cheminiai junginiai
MX2015016171A (es) 2013-06-19 2016-08-08 Seragon Pharmaceuticals Inc Moduladores del receptor de estrogeno de azetidina y usos de los mismos.
WO2014203132A1 (en) 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Substituted benzopyran compounds, compositions and uses thereof
WO2014203129A1 (en) 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Combinations of benzopyran compounds, compositions and uses thereof
BR112015031903A8 (pt) 2013-06-19 2019-12-31 Seragon Pharmaceuticals Inc composto, sal farmaceuticamente aceitável, composição farmacêutica e uso de um composto
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
WO2015028409A1 (de) 2013-08-27 2015-03-05 Bayer Pharma Aktiengesellschaft 6,7-dihydro-5h-benzo[7]annulen-derivate, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln
WO2015092634A1 (en) 2013-12-16 2015-06-25 Novartis Ag 1,2,3,4-tetrahydroisoquinoline compounds and compositions as selective estrogen receptor antagonists and degraders
CA2940576A1 (en) 2014-03-13 2015-09-17 F. Hoffmann-La Roche Ag Therapeutic combinations with estrogen receptor modulators
RU2016137150A (ru) 2014-03-13 2018-04-18 Ф. Хоффманн-Ля Рош Аг Способы и композиции для модулирования мутантов эстрогеновых рецепторов
US10420734B2 (en) 2014-03-28 2019-09-24 Duke University Method of treating cancer using selective estrogen receptor modulators
EP3233828B1 (en) 2014-12-18 2020-03-04 F. Hoffmann-La Roche AG Estrogen receptor modulators and uses thereof
ES2819448T3 (es) 2014-12-18 2021-04-16 Hoffmann La Roche Tetrahidro-pirido[3,4-b]indoles como moduladores del receptor de estrógenos y usos de los mismos
CN107406433A (zh) 2014-12-18 2017-11-28 豪夫迈·罗氏有限公司 用于治疗癌症的2,3‑二苯基色烯的衍生物
WO2016174551A1 (en) 2015-04-27 2016-11-03 Pfizer Inc. Anti-estrogenic compounds
US10053451B2 (en) 2015-05-26 2018-08-21 Genentech, Inc. Heterocyclic estrogen receptor modulators and uses thereof
KR20180012853A (ko) 2015-06-16 2018-02-06 지앙수 헨그루이 메디슨 컴퍼니 리미티드 피페리딘 유도체 및 이의 제조 방법 및 약학적 용도
HUE055321T2 (hu) 2015-10-01 2021-11-29 Olema Pharmaceuticals Inc Tetrahidro-1H-pirido[3,4-b]indol anti-ösztrogén hatóanyagok
WO2017056115A1 (en) 2015-10-03 2017-04-06 Sun Pharma Advanced Research Company Limited Novel n-aryl containing fused heterocyclic compounds
WO2017060326A1 (en) 2015-10-07 2017-04-13 F. Hoffmann-La Roche Ag Process for the preparation of (e)-3-(4-((e)-2-(2-chloro-4-fluorophenyl)-1-(1h-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid
SG10201913001SA (en) 2015-10-27 2020-03-30 Sun Pharma Advanced Res Co Ltd Novel heterocyclic antiestrogens
EP3374356A1 (en) 2015-11-09 2018-09-19 H. Hoffnabb-La Roche Ag Tetrahydronaphthalene estrogen receptor modulators and uses thereof
CA3011391C (en) 2015-11-12 2021-02-09 Zhejiang Hisun Pharmaceutical Co., Ltd. Acrylic acid derivative, preparation method and use in medicine thereof
MX2018007079A (es) 2015-12-09 2018-11-12 The Board Of Trustees Of Univ Of Illinois Reguladores a la baja del receptor de estrogeno selectivo de benzotiofeno.
WO2018081168A2 (en) 2016-10-24 2018-05-03 The Board Of Trustees Of The University Of Illinois Benzothiophene-based selective mixed estrogen receptor downregulators
AU2018205262A1 (en) 2017-01-06 2019-07-11 G1 Therapeutics, Inc. Combination therapy for the treatment of cancer

Also Published As

Publication number Publication date
US10807964B2 (en) 2020-10-20
RS63791B1 (sr) 2022-12-30
PT3386500T (pt) 2023-01-06
CA3008020A1 (en) 2017-06-15
JP2021169498A (ja) 2021-10-28
US20170166550A1 (en) 2017-06-15
IL259566B (en) 2021-09-30
US10377735B2 (en) 2019-08-13
IL259566A (en) 2018-07-31
US20220194917A1 (en) 2022-06-23
HRP20221462T1 (hr) 2023-01-20
US20200079752A1 (en) 2020-03-12
JP2019502675A (ja) 2019-01-31
SI3386500T1 (sl) 2023-01-31
ES2935125T3 (es) 2023-03-01
WO2017100712A1 (en) 2017-06-15
US11447461B2 (en) 2022-09-20
KR20180088457A (ko) 2018-08-03
EP3386968A1 (en) 2018-10-17
WO2017100715A1 (en) 2017-06-15
CN108699024B (zh) 2022-03-11
US20170166551A1 (en) 2017-06-15
CN108495628B (zh) 2022-01-11
BR112018011607A2 (pt) 2018-11-27
DK3386500T3 (da) 2022-12-12
HUE061065T2 (hu) 2023-05-28
ZA201803422B (en) 2020-08-26
AU2016366680A1 (en) 2018-07-12
US11072595B2 (en) 2021-07-27
MX2020006991A (es) 2022-07-14
CN108699024A (zh) 2018-10-23
ZA202003023B (en) 2022-12-21
CN108495628A (zh) 2018-09-04
RU2018125046A3 (pl) 2020-02-10
EP3386968A4 (en) 2019-09-25
RU2018125046A (ru) 2020-01-09
LT3386500T (lt) 2022-12-27
US20210047286A1 (en) 2021-02-18
EA201891376A1 (ru) 2019-02-28
US20200123126A1 (en) 2020-04-23
NZ743651A (en) 2023-07-28
JP6920709B2 (ja) 2021-08-18
EP3386500B1 (en) 2022-09-07
RU2747802C2 (ru) 2021-05-14
US10118910B2 (en) 2018-11-06
CA3008020C (en) 2024-02-20
BR112018011607B1 (pt) 2024-01-30
MX2018007079A (es) 2018-11-12
US20190055209A1 (en) 2019-02-21
EP3386500A4 (en) 2019-05-22
EP3386500A1 (en) 2018-10-17
AU2016366680B2 (en) 2021-06-24
EA038180B1 (ru) 2021-07-20

Similar Documents

Publication Publication Date Title
ZA202003023B (en) Benzothiophene-based selective estrogen receptor downregulators
GB201514875D0 (en) Receptor
HK1252163A1 (zh) 受體
GB201522592D0 (en) T cell receptors
HK1253695A1 (zh) T細胞受體特異性抗體
HK1256799A1 (zh) 集成的開關濾波器網絡
SG11201708313QA (en) T cell receptor
GB201702617D0 (en) Receptor
HK1256291A1 (zh) 衛生潔具沖水系統
PL3529267T3 (pl) Receptor komórek t
EP3350167A4 (en) Androgen receptor Antagonist
GB2542922B (en) Support Harness
PL3155011T3 (pl) Mutacje receptora hormonu glikoproteinowego
GB2528775B (en) Mixing device
GB2544560B (en) Mixing bowl
GB201701887D0 (en) Receptor
GB201700926D0 (en) Receptor
PL3500265T3 (pl) Selektywne ligandy receptora estrogenowego beta
GB201518991D0 (en) T cell receptors
HUE052830T2 (hu) Keverõszerkezet
GB201520136D0 (en) Fixing device for chairs
GB201515020D0 (en) Seat
GB201504285D0 (en) Receptor modulation
HUP1500233A2 (hu) Volfrám alapú metatézis katalizátorok
AU361668S (en) A swinging seat